JP2025501775A - ＳＡＲＳ－ＣｏＶ－２のスパイクタンパク質に対して特異的な抗体及びその使用 - Google Patents

ＳＡＲＳ－ＣｏＶ－２のスパイクタンパク質に対して特異的な抗体及びその使用 Download PDF

Info

Publication number
JP2025501775A
JP2025501775A JP2024539010A JP2024539010A JP2025501775A JP 2025501775 A JP2025501775 A JP 2025501775A JP 2024539010 A JP2024539010 A JP 2024539010A JP 2024539010 A JP2024539010 A JP 2024539010A JP 2025501775 A JP2025501775 A JP 2025501775A
Authority
JP
Japan
Prior art keywords
antibody
antigen
cov
binding fragment
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024539010A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025501775A5 (enExample
Inventor
リン，クオ－イー
ウォン，チー－ヒューイ
ワン，ズー－ウェン
チャン，イー－シュアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Academia Sinica
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of JP2025501775A publication Critical patent/JP2025501775A/ja
Publication of JP2025501775A5 publication Critical patent/JP2025501775A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024539010A 2021-12-27 2022-12-27 ＳＡＲＳ－ＣｏＶ－２のスパイクタンパク質に対して特異的な抗体及びその使用 Pending JP2025501775A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163266008P 2021-12-27 2021-12-27
US63/266,008 2021-12-27
PCT/US2022/082428 WO2023129928A2 (en) 2021-12-27 2022-12-27 Antibody specific to spike protein of sars-cov-2 and uses thereof

Publications (2)

Publication Number Publication Date
JP2025501775A true JP2025501775A (ja) 2025-01-23
JP2025501775A5 JP2025501775A5 (enExample) 2025-02-06

Family

ID=87000251

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024539010A Pending JP2025501775A (ja) 2021-12-27 2022-12-27 ＳＡＲＳ－ＣｏＶ－２のスパイクタンパク質に対して特異的な抗体及びその使用

Country Status (6)

Country Link
US (1) US20230279080A1 (enExample)
EP (1) EP4457243A4 (enExample)
JP (1) JP2025501775A (enExample)
CN (1) CN120787235A (enExample)
TW (1) TW202342511A (enExample)
WO (1) WO2023129928A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
CA3131096A1 (en) 2019-04-05 2020-10-08 Chi-Huey Wong Sialidase-resistant saccharide and method of making and using the same
CA3182526A1 (en) 2020-05-08 2021-11-11 Academia Sinica Chimeric influenza vaccines
WO2022221837A2 (en) 2021-04-12 2022-10-20 Academia Sinica Improved coronavirus vaccine
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
NZ825394A (en) 2023-04-08 2026-03-27 Rock Biomedical Inc Methods and compositions for dendritic cell targeting nano-delivery
CA3268566A1 (en) 2023-04-08 2024-10-17 Rock Biomedical Inc. METHODS AND COMPOSITIONS FOR TARGETED DISTRIBUTION BY POLYMERSOMES
CN121175414A (zh) 2023-05-17 2025-12-19 磐石医药生技股份有限公司 Mgat1缺乏细胞及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180243434A1 (en) * 2015-09-09 2018-08-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
JP2021533732A (ja) * 2018-07-13 2021-12-09 シャンハイ ファーマエクスプローラー カンパニー，リミティド Ｓｅｍａ４ｄ抗体及びその製造方法と使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US20110250203A1 (en) * 2008-08-29 2011-10-13 Symphogen A/S Anti-cd5 antibodies
US20190194345A1 (en) * 2015-10-05 2019-06-27 University Of Virginia Patent Foundation Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
US11370842B2 (en) * 2017-08-01 2022-06-28 City Of Hope Anti-IL1RAP antibodies
CR20220552A (es) * 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180243434A1 (en) * 2015-09-09 2018-08-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to nectin-4 and uses thereof
JP2021533732A (ja) * 2018-07-13 2021-12-09 シャンハイ ファーマエクスプローラー カンパニー，リミティド Ｓｅｍａ４ｄ抗体及びその製造方法と使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CAO, Y ET AL.: "Omicron escapes the majority ofexisting SARS-CoV-2 neutralizing antibodies", NATURE, JPN6025051268, 2022, ISSN: 0005881188 *
DE VLIEGER D ET AL.: "Single-Domain Antibodies and Their Formatting to Combat Viral Infections", ANTIBODIES (BASEL), vol. Vol. 8 (1), JPN6025051269, 20 December 2018 (2018-12-20), ISSN: 0005881186 *
HAN-YI HUANG ET AL.: "Impact of glycosylation on a broad-spectrum vaccine againstSARS-CoV-2", BIORXIV, JPN6025051267, 25 May 2021 (2021-05-25), ISSN: 0005881187 *

Also Published As

Publication number Publication date
EP4457243A2 (en) 2024-11-06
WO2023129928A3 (en) 2023-08-10
WO2023129928A2 (en) 2023-07-06
TW202342511A (zh) 2023-11-01
US20230279080A1 (en) 2023-09-07
CN120787235A (zh) 2025-10-14
EP4457243A4 (en) 2025-12-17

Similar Documents

Publication Publication Date Title
US20230279080A1 (en) Antibody specific to spike protein of sars-cov-2 and uses thereof
JP7684379B2 (ja) 抗ｓａｒｓ－ｃｏｖ－２－スパイク糖タンパク質抗体および抗原結合断片
JP7199494B2 (ja) Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体
JP7771375B2 (ja) Ｓａｒｓ－ｃｏｖ－２のタンパク質をスパイクする特異的抗体及びその使用
JP7013632B2 (ja) 自己免疫疾患を治療するための抗ｉｆｎａｒ１抗体
CN113583116B (zh) 针对SARS-CoV-1或SARS-CoV-2的抗体及其用途
EP3579875B1 (en) Anti human annexin a1 antibody
US20240083982A1 (en) Therapeutic neutralizing antibodies for sars-cov-2
HK40126868A (en) Antibody specific to spike protein of sars-cov-2 and uses thereof
TWI868567B (zh) 冠狀病毒之特異性抗體及其用途
HK40111296A (en) Antibody specific to spike protein of sars-cov-2 and uses thereof
HK40012383B (en) Anti human annexin a1 antibody
HK40012383A (en) Anti human annexin a1 antibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260609